Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Cancer Imaging. 2023 Aug 22;23(1):79. doi: 10.1186/s40644-023-00598-z.
F18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) plays a crucial role in tumour diagnosis, staging, and therapy response evaluation of various cancer types and has been a standard imaging modality used in clinical oncology practice for many years. However, it has certain limitations in evaluating some particular gastrointestinal cancer types due to low FDG-avidity or interphering physiological background activity. Fibroblast activation protein (FAP), a protein of the tumour microenvironment, is overexpressed in a wide range of cancers which makes it an attractive target for both tumour imaging and therapy. Recently, FAP-targeted radiopharmaceuticals are widely used in clinical research and achieved great results in tumour imaging. Considering the limitations of FDG PET/CT and the lack of physiological FAP-targeted tracer uptake in liver and intestinal loops, gastrointestinal cancers are among the most promising indications of FAP-targeted imaging. Herein, we present a comprehensive review of FAP-targeted imaging in gastrointestinal cancers in order to clarify the current and potential future role of this class of molecules in gastrointestinal oncology.
氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）在各种癌症类型的肿瘤诊断、分期和治疗反应评估中起着至关重要的作用，并且多年来一直是临床肿瘤学实践中标准的成像方式。然而，由于 FDG 摄取率低或干扰生理背景活性，它在评估某些特定的胃肠道癌症类型方面存在一定的局限性。成纤维细胞激活蛋白（FAP）是肿瘤微环境中的一种蛋白质，在广泛的癌症中过度表达，使其成为肿瘤成像和治疗的有吸引力的靶点。最近，FAP 靶向放射性药物在临床研究中得到了广泛应用，并在肿瘤成像方面取得了巨大的成果。考虑到 FDG PET/CT 的局限性以及肝脏和肠袢中缺乏生理性 FAP 靶向示踪剂摄取，胃肠道癌症是 FAP 靶向成像最有前途的适应症之一。在此，我们对胃肠道癌症中的 FAP 靶向成像进行了全面综述，以阐明这类分子在胃肠道肿瘤学中的当前和潜在未来作用。
